VEGFA and age-related macular degeneration: The ANCHOR (ANti-VEGF antibody for the treatment of predominantly classic CHORoidal neovascularization in age-related macular degeneration) study [2] demonstrated that ranibizumab provided greater clinical benefit after 2 years than verteporfin PDT in patients with age-related macular degeneration with new-onset, predominantly classic CNV.